GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (4)
  • 1
    In: Cancer Immunology Research, American Association for Cancer Research (AACR), Vol. 9, No. 7 ( 2021-07-01), p. 779-789
    Abstract: A crucial mode of action of trastuzumab is the labeling of HER2-positive (HER2+) tumor cells for the eradication by natural killer (NK) cells, a process called antibody-dependent cellular cytotoxicity (ADCC). However, despite widespread HER2 expression among cancer entities, only a fraction, with robust HER2 overexpression, benefits from trastuzumab therapy. ADCC requires both sufficient lymphocytic infiltration and close binding of the immune cells to the antibody-tagged tumor cells. We hypothesized that the chemokine CX3CL1 could improve both processes, as it is synthesized as a membrane-bound, adhesive form that is eventually cleaved into a soluble, chemotactic protein. Here, we show that CX3CL1 overexpression is a positive prognostic marker in breast cancer. CX3CL1 overexpression attracted tumor-suppressive lymphocytes, including NK cells, and inhibited tumor growth and lung metastasis in the syngeneic 4T1 breast cancer mouse model. In HER2+ SKBR3, MDA-MB-453, and HT-29 tumor cells, CX3CL1 overexpression increased NK cell–mediated cytotoxicity in vitro and acted synergistically with trastuzumab. Even though CX3CL1 did not further improve trastuzumab efficacy in vivo in the trastuzumab-sensitive MDA-MB-453 model, it compensated for NK-cell depletion and prolonged survival. In the HER2 low–expressing HT-29 model, however, CX3CL1 overexpression not only prolonged survival time but also overcame trastuzumab resistance in a partly NK cell–dependent manner. Taken together, these findings identify CX3CL1 as a feasible pharmacologic target to enable trastuzumab therapy in HER2 low–expressing cancers and render it a potential predictive biomarker to determine therapy responders.
    Type of Medium: Online Resource
    ISSN: 2326-6066 , 2326-6074
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2732517-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 16 ( 2014-08-15), p. 4318-4328
    Abstract: CD40, a member of the TNF receptor family, is expressed on all mature B cells and on most B-cell lymphomas. Recently, we have shown that constitutive activation of CD40 signaling in B cells induced by a fusion protein consisting of the transmembrane part of the Epstein–Barr viral latent membrane protein 1 (LMP1) and the cytoplasmic part of CD40 (LMP1/CD40) drives B-cell lymphoma development in transgenic mice. Because LMP1/CD40-expressing B cells showed an upregulation of CD19, we investigated CD19's function in CD40-driven B-cell expansion and lymphomagenesis. Here, we demonstrate that ablation of CD19 in LMP1/CD40 transgenic mice resulted in a severe loss and reduced lifespan of mature B cells and completely abrogated development of B-cell lymphoma. CD19 is localized to lipid rafts and constitutively activated by the LMP1/CD40 fusion protein in B cells. We provide evidence that the improved survival and malignant transformation of LMP1/CD40-expressing B cells are dependent on activation of the MAPK Erk that is mediated through CD19 in a PI3K-dependent manner. Our data suggest that constitutively active CD40 is dependent on CD19 to transmit survival and proliferation signals. Moreover, we detected a similarly functioning prosurvival pathway involving phosphorylated CD19 and PI3K-dependent Erk phosphorylation in human diffuse large B-cell lymphoma cell lines. Our data provide evidence that CD19 plays an important role in transmitting survival and proliferation signals downstream of CD40 and therefore might be an interesting therapeutic target for the treatment of lymphoma undergoing chronic CD40 signaling. Cancer Res; 74(16); 4318–28. ©2014 AACR.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 14_Supplement ( 2020-07-15), p. B51-B51
    Abstract: MondoA (also known as MLXIP, MAX-like protein X interacting protein) is a metabolic stress sensor and a proglycolytic transcription factor potentially involved in metabolic addiction features of leukemia and the Warburg effect. MondoA dimerizes with MLX within the MYC interactome and promotes longevity in C. elegans (Johnson et al., 2014). The MYC interactome comprises the MYC/MAX/MNT/MLX/MLXIP transcription factor network: Its key players MYC, MNT and MLXIP differentially mediate proliferation, differentiation, or metabolism by heterodimerization with MAX or MLX. We previously described MondoA to promote malignancy of common precursor B-cell acute lymphoblastic leukemia (cALL). MondoA knockdown (MKD) in cALL cell lines in xenografted mice reduced the number of leukemic blasts (Sipol, 2014). Here we report that MondoA high expression was observed in ALL subtypes with no MYC overexpression. RNA-sequencing data of 132 primary ALL bone marrow samples confirmed the inverse correlation of MYC and MondoA. Interestingly, in subgroups of ALL with low MYC expression and high MondoA (cALL with BCR-ABL, cALL with TCF3-PBX, cALL with ETV6-RUNX1, and cALL with hyperdiploid karyotype), metabolic gene sets did not appear as upregulated. In contrast, cALL samples with high MYC expression and low MondoA (proB-ALL with MLL rearrangements and B-ALL with IGH-MYC fusion gene) demonstrated upregulation of pathways for oxidative phosphorylation and fatty acid metabolism in addition to targets of E2F, G2M checkpoints, and MYC targets. Using CRISPR/CAS9-mediated knockout (MKO), we demonstrate that MondoA dials down MYC-induced metabolic stress and increases leukemia stress resistance. By limiting mitochondrial pyruvate dehydrogenase (PDH) activity in PDHK1 (pyruvate dehydrogenase kinase 1)-dependent manner, MondoA decreases oxidative phosphorylation. In line with limiting effect of MondoA on oxidative phosphorylation, we observed that MondoA decreases ROS generation in B cells. In conclusion, MondoA is restricting MYC-target gene expression to promote leukemia cell survival by facilitating glycolysis and adaption to oxidative stress. MondoA limits pyruvate availability for the TCA cycle by decreasing PDH activity, thus ensuring consistent glycolytic flux, mediating the Warburg effect, and insuring integrity of leukemia metabolism and ROS balancing in response to oncogene activation. Citation Format: Alexandra Sipol, Erik Hameister, Andreas Petry, Agnes Görlach, Jürgen Ruland, Guenther Richter, Stefan Burdach, Poul Sorensen. Adaptation to oncogene-induced metabolic stress by MondoA (MLXIP) drives common acute lymphoblastic leukemia (cALL) malignancy [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr B51.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2015
    In:  Cancer Immunology Research Vol. 3, No. 7 ( 2015-07-01), p. 721-726
    In: Cancer Immunology Research, American Association for Cancer Research (AACR), Vol. 3, No. 7 ( 2015-07-01), p. 721-726
    Abstract: Caspase recuitment domain–containing protein 9 (CARD9) functions in different inflammation pathways to elicit responses to microbial signals and is known to affect intestinal inflammation. Examining the APCmin mouse model of intestinal tumorigenesis and using stringently controlled, sex- and age-matched pairs of CARD9-competent and CARD9-deficient mice, we have found that CARD9 has a restricted but strong effect on tumorigenesis in the large intestine. We have found that CARD9 reduces viability specifically in males and promotes tumorigenesis specifically in the large intestines of these male mice. To our knowledge, this is the first gene ablation in APCmin mice that solely affects colon tumors in male subjects and, as such, may have significant clinical implications. Additional data suggest correlative disruption of plasma cytokine expression and immune infiltration of the tumors. We speculate that known sex-specific differences in human colorectal cancer may involve inflammation, particularly CARD9-dependent inflammation. Cancer Immunol Res; 3(7); 721–6. ©2015 AACR.
    Type of Medium: Online Resource
    ISSN: 2326-6066 , 2326-6074
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2732517-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...